One research goal of Herscu Laboratory is developing the science behind personalized medicine. Research in this area is aimed at helping the pharmaceutical industry and medical care providers target the right drug for the right person the first time around, lessening side effects and enhancing patient response.
Besides developing predictive tools on drug efficacy, side effects, and sub-classification of patient populations, Herscu Laboratory is interested in applying multi-disciplinary research and understanding to the drug development process, leading to novel tools for the screening and selection of molecules of interest.
Development of Pharmacological Compounds
Herscu Laboratory in conjunction with Whewell Biosciences is involved in research and development in ethnobotany to uncover pharmacologically active molecules with potential relevance for medical use or describe novel uses for existing compounds. Beyond discovering valuable treatments, the goal is to minimize guesswork and wasted effort in the process by creating intelligent and efficient processes for linking new compounds to potential usage.
The first molecule, currently being researched in animal testing phase at Central Michigan University, is for the treatment of ADHD.
A second molecule is in early phase development for Type II Diabetes.
Autistic Spectrum Disorders
A third substance, also in early stages of development, is aimed at the treatment of autistic spectrum disorder.
Evolution of the Drug Development Process
Herscu Laboratory is partnering with Personalized Pharmaceutical Solutions (PPS) to research improvements in the entire drug development pathway, from efficiently identifying the full range of potential uses for new and existing drugs, to intelligent shepherding of drugs through the development process and phase I-IV trials. The goal of research into the drug development pathway is minimizing guesswork by identifying relevant subgroups within study populations and tying efficacy and adverse effects to these clinically identifiable subgroups.
Clinical Trial Enhancement
Herscu Laboratory, in conjunction with Personalized Pharmaceutical Solutions (PPS), is developing tools to enhance the success of clinical trials through identification of homogeneous subgroups with unique clinical outcomes, either in terms of efficacy or adverse effects. By extracting predictable subgroups based on individual phenomes and physiomes that will respond in unique ways to a drug, trials can be focused to examine effect only within the most relevant clinical populations, enhancing drug efficacy and benefiting patients. Research is ongoing in multiple distinct areas:
Herscu Laboratory is currently working on the development of predictive tools for ACE-I angioedema occurrence, severity, and diagnosis. Multiple aspects of the project are ongoing with different partners. In conjunction with PPS, Herscu Laboratory has produced a systematic review of the angioedema pathomechanism, as well as a case series review and emergency room study on angioedema severity and occurrence. The goal of this research area is the creation of clinical prediction guides to help diagnose angioedema occurrence and subtypes, as well as direct appropriate treatment response. Herscu Laboratory, in conjunction with PPS, is in the process of publishing our findings on ACE-I angioedema occurrence, clinical characteristics, diagnosis, and treatment implications.
ADHD Drug Research
Herscu Laboratory and PPS are developing initial research into ADHD sub-typing and prediction of individual treatment response for specific pharmaceuticals. Research will examine how clinical sub-types affect drug treatment efficacy and adverse effect reactions. The goal is to develop clinical prediction tools that refine ADHD diagnostics and thus treatment targeting success.
Clinical Prediction Guides (CPGs)
Herscu Laboratory and PPS have developed an overview paper on Clinical Prediction Guides and Rules (CPG and CPR) describing the development process, current usage and quality, and their relationship to personalized medicine.